Prevalence and risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae

Journal of Infection and Chemotherapy

Volumn 22, Issue 5, 2016, Pages 319-326

  Nakai, Hazuki ^a   Hagihara, Mao ^b   Kato, Hideo ^b   Hirai, Jun ^a   Nishiyama, Naoya ^b   Koizumi, Yusuke ^b   Sakanashi, Daisuke ^b   Suematsu, Hiroyuki ^b   Yamagishi, Yuka ^b   Mikamo, Hiroshige ^a,b  

^a AICHI MEDICAL UNIVERSITY   (Japan)

^b AICHI MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Enterobacteriaceae; Escherichia coli; Extended spectrum lactamase (ESBL); Klebsiella oxytoca; Klebsiella pneumoniae; Proteus mirabilis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEPHALOSPORIN; COTRIMOXAZOLE; OXAZOLIDINONE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM IDENTIFICATION; CHILD; COMMUNITY ACQUIRED INFECTION; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; HEALTHCARE ASSOCIATED INFECTION; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; INFANT; JAPAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; NEWBORN; NONHUMAN; OUTPATIENT; PREVALENCE; PROTEUS MIRABILIS; RISK FACTOR; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; MICROBIOLOGY; MIDDLE AGED; PRESCHOOL CHILD; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CHILD; CHILD, PRESCHOOL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84960982203     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2016.02.004     Document Type: Article

References (31)

1. Ikeda Y., Mamiya T., Nishiyama H., Koseki T., Mouri A., Nabeshima T. Risk factors for extended-spectrum beta-lactamase-producing Escherichia coli infection in hospitalized patients. Nagoya J Med Sci 2012, 74:105-114.
2. Ben-Ami R., Rodríguez-Baño J., Arslan H., Pitout J.D., Quentin C., Calbo E.S., et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009, 49:682-690.
3. Luvsansharav U.O., Hirai I., Niki M., Sasaki T., Makimoto K., Komalamisra C., et al. Analysis of risk factors for a high prevalence of extended-spectrum (beta}-lactamase-producing Enterobacteriaceae in asymptomatic individuals in rural Thailand. J Med Microbiol 2011, 60:619-624.
4. Li B., Sun J.Y., Liu Q.Z., Han L.Z., Huang X.H., Ni Y.X. High prevalence of CTX-M β-lactamases in faecal Escherichia coli strains from healthy humans in Fuzhou, China. Scand J Infect Dis 2011, 43:170-174.
5. Biehl L.M., Schmidt-Hieber M., Liss B., Cornely O.A., Vehreschild M.J. Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients - review of the literature from a clinical perspective. Crit Rev Microbiol 2014, [Epub ahead of print].
6. Lin S.P., Liu M.F., Lin C.F., Shi Z.Y. Phenotypic detection and polymerase chain reaction screening of extended-spectrum β-lactamases produced by Pseudomonas aeruginosa isolates. J Microbiol Immunol Infect 2012, 45:200-207.
7. Alsterlund R., Carlsson B., Gezelius L., Haeggman S., Olsson-Liljequist B. Multiresistant CTX-M-15 ESBL-producing Escherichia coli in southern Sweden: description of an outbreak. Scand J Infect Dis 2009, 41:410-415.
8. Lytsy B., Sandegren L., Tano E., Torell E., Andersson D.I., Melhus A. The first major extended-spectrum beta-lactamase outbreak in Scandinavia was caused by clonal spread of a multiresistant Klebsiella pneumoniae producing CTX-M-15. APMIS 2008, 116:302-308.
9. Kaya O., Akcam F.Z., Gonen I., Unal O., Ceylan T. Risk factors for bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in a Turkish hospital. J Infect Dev Ctries 2013, 7:507-512.
10. Hyle E.P., Lipworth A.D., Zaoutis T.E., Nachamkin I., Bilker W.B., Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection. Arch Intern Med 2005, 165:1375-1380.
11. Schwaber M.J., Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007, 60:913-920.
12. Chen C.H., Huang C.C. Risk factor analysis for extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections in central Taiwan. BMC Infect Dis 2013, 13:417.
13. Oteo J., Navarro C., Cercenado E., Delgado-Iribarren A., Wilhelmi I., Orden B., et al. Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long term care facilities and hospital institutions. J Clin Microbiol 2006, 44:2359-2366.
14. Rodríguez-Baño J., Picón E., Gijón P., Hernández J.R., Ruíz M., Peña C., et al. Community-onset bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010, 50:40-48.
15. Enoch D.A., Brown F., Sismey A.W., Mlangeni D.A., Curran M.D., Karas J.A., et al. Epidemiology of extended-spectrum beta-lactamase-producing Enterobacteriaceae in a UK district hospital; an observational study. J Hosp Infect 2012, 81:270-277.
16. Shitrit P., Reisfeld S., Paitan Y., Gottesman B.S., Katzir M., Paul M., et al. Extended-spectrum beta-lactamase-producing Enterobacteriaceae carriage upon hospital admission: prevalence and risk factors. J Hosp Infect 2013, 85:230-232.
17. Albur M.S., Noel A., Bowker K., MacGowan A. The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments. Int J Antimicrob Agents 2015, 46:560-567.
18. Kohno S., Imamura Y., Shindo Y., Seki M., Ishida T., Teramoto S., et al. Clinical practice guidelines for nursing- and healthcare-associated pneumonia (NHCAP). Respir Investig 2013, 51:103-126.
19. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 2009, CLSI document M07-A8, Clinical and Laboratory Standards Institute, Wayne, PA. 8th ed.
20. Steinke D.T., Seaton R.A., Phillips G., MacDonald T.M., Davey P.G. Prior trimethoprim use and trimethoprim-resistant urinary tract infection: a nested case-control study with multivariate analysis for other risk factors. J Antimicrob Chemother 2001, 47:781-787.
21. Safdar N., Maki D.G. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002, 136:834-844.
22. Park Y.S., Bae I.K., Kim J., Jeong S.H., Hwang S.S., Seo Y.H., et al. Risk factors and molecular epidemiology of community-onset extended-spectrum β-lactamase-producing Escherichia coli bacteremia. Yonsei Med J 2014, 55:467-475.
23. Sato T., Hara T., Horiyama T., Kanazawa S., Yamaguchi T., Maki H. Mechanism of resistance and antibacterial susceptibility in extended-spectrum β-lactamase phenotype Klebsiella pneumoniae and Klebsiella oxytoca isolated between 2000 and 2010 in Japan. J Med Microbiol 2015, 64:538-543.
24. Hara T., Sato T., Horiyama T., Kanazawa S., Yamaguchi T., Maki H. Prevalence and molecular characterization of CTX-M extended-spectrum β-lactamase-producing Escherichia coli from 2000 to 2010 in Japan. Jpn J Antibiot 2015, 68:75-84.
25. Matsumura Y., Yamamoto M., Nagao M., Komori T., Fujita N., Hayashi A., et al. Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-β-lactamase-producing Escherichia coli bacteremia. Antimicrob Agents Chemother 2015, 59:5107-5113.
26. Luvsansharav U.O., Hirai I., Nakata A., Imura K., Yamauchi K., Niki M., et al. Prevalence of and risk factors associated with faecal carriage of CTX-M b-lactamase-producing Enterobacteriaceae in rural Thai communities. J Antimicrob Chemother 2012, 67:1769-1774.
27. Cheng M.F., Chen W.L., Hung W.Y., Huang I.F., Chiou Y.H., Chen Y.S., et al. Emergence of extended spectrum-β-lactamase-producing Escherichia coli O25b-ST131: a major community-acquired uropathogen in infants. Pediatr Infect Dis J 2015, 34:469-475.
28. Guillet M., Bille E., Lecuyer H., Taieb F., Masse V., Lanternier F., et al. Epidemiology of patients harboring extended-spectrum beta-lactamase-producing enterobacteriaceae (ESBLE), on admission. Med Mal Infect 2010, 40:632-636.
29. Wiener J., Quinn J.P., Bradford P.A., Goering R.V., Nathan C., Bush K., et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999, 281:517-523.
30. Shigehara K., Uchibayashi T., Maeda E., Namiki M. Detection of drug-resistant Escherichia coli in patients with complicated cystitis: analysis of risk factors. Int J Urol 2009, 16:808-812.
31. Park S.H., Choi S.M., Chang Y.K., Lee D.G., Cho S.Y., Lee H.J., et al. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli. J Antimicrob Chemother 2014, 69:2848-2856.